A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Interleukin-12
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top